STATEMENT: THERYQ and Gustave Roussy have been selected for the "FLASHDEEP" project

(Information sent by the signatory company).

STATEMENT: THERYQ and Gustave Roussy have been selected for the "FLASHDEEP" project

(Information sent by the signatory company)

THERYQ and Gustave Roussy have been selected within the framework of the "i-Démo" France 2030 call for projects, managed by Bpifrance on behalf of the French government, for the "FLASHDEEP" project, for an amount of 38 million euros.

ROUSSET, France, February 2, 2024 /PRNewswire/ -- THERYQ, a French company specialized in the development of FLASH radiotherapy systems, and Gustave Roussy, the first French and European cancer research center, fourth in the world, are selected within the framework of the "i-Démo" / France 2030 call for projects for the "FLASHDEEP" project, with a budget of 38 million euros.

FLASHDEEP will be the world's first FLASH radiotherapy device using very high energy electrons (VHEE; > 100 MeV). The particle acceleration technology developed by THERYQ arises from research initiated by the European Organization for Nuclear Research (CERN) and the Lausanne University Hospital (CHUV).

The first FLASHDEEP clinical device will be installed in France, at Gustave Roussy, at the end of 2026, for clinical trials with eligible patients. This system will be able to treat deep solid tumors of up to 20 cm thanks to a high-energy electron beam and a dose rate a thousand times higher than that used in conventional radiotherapy. FLASHDEEP represents an important technological advance in the fight against cancer, offering the prospect of a more effective, better tolerated, shorter and, therefore, cheaper treatment than conventional radiotherapy, with no equivalent on the current market.

«THERYQ's mission is to revolutionize cancer treatment by launching a new radiotherapy process called "FLASH". An advanced technique that aims to reduce irradiation time to just a fraction of a second, thus replacing multiple sessions of radiotherapy while preserving the patient's healthy tissues. "This technology offers the opportunity to treat more cancers resistant to current radiotherapy treatments, paving the way for a more effective, less invasive and less toxic treatment for cancer patients," said Ludovic Le Meunier, CEO of THERYQ. He added : "Thanks to this funding obtained after an excellent collaboration with the DGE and Bpifrance, THERYQ aims to make all types of solid cancer a manageable disease, allowing FLASH radiotherapy to unleash its curative potential."

«By irradiating more than 3,000 times faster, we can achieve the same antitumor effect with fewer toxicities and fewer side effects or increase the irradiation dose in resistant tumors for cancers with less favorable prognoses. The French company THERYQ is the first to have demonstrated the "FLASH" effect based on the use of electrons emitted at very high speeds. The first trials will begin in 2027 and will focus on inoperable pancreatic and brain cancers. But before that, we need to deepen our knowledge in radiobiology and medical physics to develop new dose calculation methods linked to this new technology," explained Professor Eric Deutsch, head of the Department of Radiotherapy at Gustave Roussy.

Thanks to the funding provided by Bpifrance within the framework of France 2030, THERYQ and Gustave Roussy will bring together biologists, physicists and doctors to carry out the preclinical and clinical studies necessary to demonstrate the improved tolerance and effectiveness of FLASHDEEP compared to radiotherapy conventional. They will also present the application for CE marking so that French and European patients who need it can benefit from this new therapeutic option as soon as possible.

In parallel, THERYQ plans to build and equip its industrial platform to allow the launch of the first machines, followed by the mass production of FLASHDEEP devices and the start of their commercialization in Europe. This industrial deployment project also represents a great economic opportunity for France, with the creation of more than 600 direct and indirect jobs in the country. Ultimately, it will lead to the revival of the French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

Merryl Marcout - Press Relations - AZAPHARM Fatine Slaoui, THERYQ - Claire Parisel, Gustave Roussy,

Logo - -

View original content to download multimedia: